Back
Science

Research Studies Investigate Blood Biomarker pTau217 for Early Detection and Prediction of Alzheimer's Disease and Other Conditions

Generated on: Last updated: 8 sources
View source

Blood Biomarker pTau217 Shows Promise for Early Alzheimer's Detection and Prediction

Multiple studies suggest that levels of the pTau217 protein in blood plasma may predict the development of Alzheimer's pathology and the future onset of cognitive symptoms years, and in some cases decades, in advance.

A series of recent research studies has investigated the potential of a blood-based biomarker, phosphorylated tau 217 (pTau217), for the early detection of Alzheimer's disease pathology and the prediction of future cognitive decline. Separate findings also indicate that elevated levels of this protein may be associated with other medical conditions, not exclusively Alzheimer's.

Summary of Key Research Findings

Multiple studies, published in journals including Nature Medicine, Nature Communications, and JAMA Network Open, report that levels of the pTau217 protein in blood plasma appear to correlate with the accumulation of amyloid and tau proteins in the brain, which are hallmarks of Alzheimer's disease.

Research suggests these blood measurements may predict the development of Alzheimer's pathology and the future onset of cognitive symptoms years, and in some cases decades, in advance. However, scientists note that blood tests for Alzheimer's are not yet recommended for routine screening in asymptomatic individuals and require further validation.

Study Details and Predictive Models

A study led by researchers at Washington University School of Medicine in St. Louis, involving 603 older adults, developed a model using pTau217 levels to estimate the time until Alzheimer's symptom onset. The model, described in Nature Medicine, forecasts symptom appearance within an approximate window of three to four years.

  • The research indicates that the interval between elevated pTau217 levels and symptom onset varies with age.
  • According to the model, an individual with elevated pTau217 at age 60 might develop symptoms approximately 20 years later, while an elevation detected at age 80 might be followed by symptoms in about 11 years.
  • The research team has made their model development code and a web-based application publicly available for further investigation.

Long-Term Prediction and Demographic Factors

Other studies have examined pTau217's predictive power over longer periods and in specific populations.

  • A study from Mass General Brigham, published in Nature Communications, followed 317 cognitively healthy participants aged 50-90 for an average of eight years. It found that rising pTau217 levels could predict Alzheimer's pathology development before abnormalities were visible on amyloid PET scans.
  • Research from the University of California San Diego, published in JAMA Network Open, analyzed decades-old blood samples from 2,766 women. It found an association between higher pTau217 levels and the subsequent development of mild cognitive impairment or dementia up to 25 years later. The study noted the biomarker was a stronger predictor in women over 70, those with the APOE ε4 genetic risk factor, and those who had received certain hormone therapies. The authors stated the findings might not apply to men or younger populations.

Potential Applications and Current Limitations

Researchers highlight several potential applications for pTau217 testing, while also outlining current limitations.

Potential Applications:

  • Clinical Trials: Could make trials for preventive Alzheimer's treatments more efficient by helping to enroll participants earlier in the disease process.
  • Research Acceleration: Blood-based biomarkers are considered less invasive and more accessible than brain imaging or spinal fluid tests.
  • Future Clinical Use: With further refinement, models might eventually inform individual patients about their risk timeline to aid in planning or preventive strategies.

Current Limitations & Cautions:

  • Scientists from multiple studies explicitly state that pTau217 or other Alzheimer's biomarker tests are not currently recommended for screening cognitively unimpaired individuals outside of research settings.
  • A study published in Nature Medicine by researchers in Germany found that elevated pTau levels in blood were also present in individuals with two forms of systemic amyloidosis, indicating pTau is not a specific marker for Alzheimer's disease alone.
  • Larger and more diverse study populations are needed to validate findings and improve prediction algorithms.
  • No single test can definitively predict Alzheimer's risk years in advance, and the presence of protein accumulations does not always progress to dementia.

Researcher Statements

"We used to think that PET scan detection was the earliest sign... But now we are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans."
— Hyun-Sik Yang of Mass General Brigham

  • Suzanne Schindler of Washington University said the work demonstrates the feasibility of using blood tests to predict symptom onset and that such models could accelerate research and clinical trials.
  • Mathias Jucker, involved in the systemic amyloidosis study, noted the results show high pTau levels "are not specific to Alzheimer's disease" and can signify other amyloid diseases, which may offer new diagnostic opportunities for those conditions.